Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan

Kun Ming Rau, Fu Ou-Yang, Ta Chung Chao, Yao-Lung Kuo, Tsui Fen Cheng, Tsu Yi Chao, Dar Ren Chen, Yen Dun Tzeng, Being Whey Wang, Chun Yu Liu, Ming Hung Hu, Yin Che Lu, Wei Jen Ou, Chin Ho Kuo, Chieh Han Chuang, Jung Yu Kan, Fang Ming Chen, Ming Feng Hou

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer. Methods: This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer. Results: The survival rate at 24 months was 57.2% (95% CI 51.0–62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45–3.94). A total of 175 patients (40.1%) received eribulin for fewer than 90 days and the others received it for 90 days or more. Eight patients (1.83%) had complete remission, 82 (18.8%) had partial remission, 202 (46.3%) had stable disease, and 144 (33.0%) had progressive disease (PD). Patients’ tumors with the luminal A subtype had a significantly better objective response rate. Kaplan–Meier analysis indicated that hormone receptor positivity, luminal A subtype, receipt of eribulin as the 1st to 3rd line therapy, and metastasis to fewer than 4 organs were significantly associated with longer TTF. Stepwise multivariate analysis showed that only receipt of eribulin as the 1st to 3rd line therapy was significantly associated with TTF (HR 1.49, p < 0.001). All toxicities were manageable and only 18 patients (4.1%) discontinued treatment due to adverse events. Conclusions: Eribulin appears to have better efficacy and cause fewer adverse events, especially neutropenia, in Taiwanese women than Western women.

Original languageEnglish
Pages (from-to)583-591
Number of pages9
JournalBreast Cancer Research and Treatment
Volume170
Issue number3
DOIs
Publication statusPublished - 2018 Aug 1

Fingerprint

eribulin
Taiwan
Observational Studies
Retrospective Studies
Breast Neoplasms
Treatment Failure
Therapeutics
Neutropenia
Multivariate Analysis
Survival Rate
Hormones

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Rau, Kun Ming ; Ou-Yang, Fu ; Chao, Ta Chung ; Kuo, Yao-Lung ; Cheng, Tsui Fen ; Chao, Tsu Yi ; Chen, Dar Ren ; Tzeng, Yen Dun ; Wang, Being Whey ; Liu, Chun Yu ; Hu, Ming Hung ; Lu, Yin Che ; Ou, Wei Jen ; Kuo, Chin Ho ; Chuang, Chieh Han ; Kan, Jung Yu ; Chen, Fang Ming ; Hou, Ming Feng. / Effect of eribulin on patients with metastatic breast cancer : multicenter retrospective observational study in Taiwan. In: Breast Cancer Research and Treatment. 2018 ; Vol. 170, No. 3. pp. 583-591.
@article{aa513f37a5cb4aaa888a635e647a98e3,
title = "Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan",
abstract = "Purpose: The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer. Methods: This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer. Results: The survival rate at 24 months was 57.2{\%} (95{\%} CI 51.0–62.9{\%}) and the median time to treatment failure (TTF) was 3.91 months (95{\%} CI 3.45–3.94). A total of 175 patients (40.1{\%}) received eribulin for fewer than 90 days and the others received it for 90 days or more. Eight patients (1.83{\%}) had complete remission, 82 (18.8{\%}) had partial remission, 202 (46.3{\%}) had stable disease, and 144 (33.0{\%}) had progressive disease (PD). Patients’ tumors with the luminal A subtype had a significantly better objective response rate. Kaplan–Meier analysis indicated that hormone receptor positivity, luminal A subtype, receipt of eribulin as the 1st to 3rd line therapy, and metastasis to fewer than 4 organs were significantly associated with longer TTF. Stepwise multivariate analysis showed that only receipt of eribulin as the 1st to 3rd line therapy was significantly associated with TTF (HR 1.49, p < 0.001). All toxicities were manageable and only 18 patients (4.1{\%}) discontinued treatment due to adverse events. Conclusions: Eribulin appears to have better efficacy and cause fewer adverse events, especially neutropenia, in Taiwanese women than Western women.",
author = "Rau, {Kun Ming} and Fu Ou-Yang and Chao, {Ta Chung} and Yao-Lung Kuo and Cheng, {Tsui Fen} and Chao, {Tsu Yi} and Chen, {Dar Ren} and Tzeng, {Yen Dun} and Wang, {Being Whey} and Liu, {Chun Yu} and Hu, {Ming Hung} and Lu, {Yin Che} and Ou, {Wei Jen} and Kuo, {Chin Ho} and Chuang, {Chieh Han} and Kan, {Jung Yu} and Chen, {Fang Ming} and Hou, {Ming Feng}",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s10549-018-4778-y",
language = "English",
volume = "170",
pages = "583--591",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

Rau, KM, Ou-Yang, F, Chao, TC, Kuo, Y-L, Cheng, TF, Chao, TY, Chen, DR, Tzeng, YD, Wang, BW, Liu, CY, Hu, MH, Lu, YC, Ou, WJ, Kuo, CH, Chuang, CH, Kan, JY, Chen, FM & Hou, MF 2018, 'Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan', Breast Cancer Research and Treatment, vol. 170, no. 3, pp. 583-591. https://doi.org/10.1007/s10549-018-4778-y

Effect of eribulin on patients with metastatic breast cancer : multicenter retrospective observational study in Taiwan. / Rau, Kun Ming; Ou-Yang, Fu; Chao, Ta Chung; Kuo, Yao-Lung; Cheng, Tsui Fen; Chao, Tsu Yi; Chen, Dar Ren; Tzeng, Yen Dun; Wang, Being Whey; Liu, Chun Yu; Hu, Ming Hung; Lu, Yin Che; Ou, Wei Jen; Kuo, Chin Ho; Chuang, Chieh Han; Kan, Jung Yu; Chen, Fang Ming; Hou, Ming Feng.

In: Breast Cancer Research and Treatment, Vol. 170, No. 3, 01.08.2018, p. 583-591.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of eribulin on patients with metastatic breast cancer

T2 - multicenter retrospective observational study in Taiwan

AU - Rau, Kun Ming

AU - Ou-Yang, Fu

AU - Chao, Ta Chung

AU - Kuo, Yao-Lung

AU - Cheng, Tsui Fen

AU - Chao, Tsu Yi

AU - Chen, Dar Ren

AU - Tzeng, Yen Dun

AU - Wang, Being Whey

AU - Liu, Chun Yu

AU - Hu, Ming Hung

AU - Lu, Yin Che

AU - Ou, Wei Jen

AU - Kuo, Chin Ho

AU - Chuang, Chieh Han

AU - Kan, Jung Yu

AU - Chen, Fang Ming

AU - Hou, Ming Feng

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Purpose: The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer. Methods: This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer. Results: The survival rate at 24 months was 57.2% (95% CI 51.0–62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45–3.94). A total of 175 patients (40.1%) received eribulin for fewer than 90 days and the others received it for 90 days or more. Eight patients (1.83%) had complete remission, 82 (18.8%) had partial remission, 202 (46.3%) had stable disease, and 144 (33.0%) had progressive disease (PD). Patients’ tumors with the luminal A subtype had a significantly better objective response rate. Kaplan–Meier analysis indicated that hormone receptor positivity, luminal A subtype, receipt of eribulin as the 1st to 3rd line therapy, and metastasis to fewer than 4 organs were significantly associated with longer TTF. Stepwise multivariate analysis showed that only receipt of eribulin as the 1st to 3rd line therapy was significantly associated with TTF (HR 1.49, p < 0.001). All toxicities were manageable and only 18 patients (4.1%) discontinued treatment due to adverse events. Conclusions: Eribulin appears to have better efficacy and cause fewer adverse events, especially neutropenia, in Taiwanese women than Western women.

AB - Purpose: The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer. Methods: This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer. Results: The survival rate at 24 months was 57.2% (95% CI 51.0–62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45–3.94). A total of 175 patients (40.1%) received eribulin for fewer than 90 days and the others received it for 90 days or more. Eight patients (1.83%) had complete remission, 82 (18.8%) had partial remission, 202 (46.3%) had stable disease, and 144 (33.0%) had progressive disease (PD). Patients’ tumors with the luminal A subtype had a significantly better objective response rate. Kaplan–Meier analysis indicated that hormone receptor positivity, luminal A subtype, receipt of eribulin as the 1st to 3rd line therapy, and metastasis to fewer than 4 organs were significantly associated with longer TTF. Stepwise multivariate analysis showed that only receipt of eribulin as the 1st to 3rd line therapy was significantly associated with TTF (HR 1.49, p < 0.001). All toxicities were manageable and only 18 patients (4.1%) discontinued treatment due to adverse events. Conclusions: Eribulin appears to have better efficacy and cause fewer adverse events, especially neutropenia, in Taiwanese women than Western women.

UR - http://www.scopus.com/inward/record.url?scp=85045123404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045123404&partnerID=8YFLogxK

U2 - 10.1007/s10549-018-4778-y

DO - 10.1007/s10549-018-4778-y

M3 - Article

C2 - 29623575

AN - SCOPUS:85045123404

VL - 170

SP - 583

EP - 591

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -